Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of HO (Heme Oxygenase)-1 inhibitor in preparing medicine for inhibiting doxorubicin-induced cardiotoxicity

A technology of heme oxygenase and cardiotoxicity, applied in drug combinations, pharmaceutical formulations, organic active ingredients, etc., can solve the problems of limitations in the clinical application of doxorubicin, affecting the quality of life of patients, and the mechanism of myocardial injury is not fully understood

Active Publication Date: 2017-09-22
ZHEJIANG UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This not only greatly affects the quality of life of patients, but also greatly limits the clinical application of adriamycin.
[0003] The toxicity of doxorubicin to the heart is to cause myocardial damage in a cumulative and dose-dependent manner, but the mechanism of myocardial damage is still not fully understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of HO (Heme Oxygenase)-1 inhibitor in preparing medicine for inhibiting doxorubicin-induced cardiotoxicity
  • Application of HO (Heme Oxygenase)-1 inhibitor in preparing medicine for inhibiting doxorubicin-induced cardiotoxicity
  • Application of HO (Heme Oxygenase)-1 inhibitor in preparing medicine for inhibiting doxorubicin-induced cardiotoxicity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0015] The present invention will be further described below in conjunction with specific examples, but the protection scope of the present invention is not limited thereto.

[0016] 1. Materials and Methods

[0017] 1.1 Experimental animals

[0018] Six-week-old SPF grade C57BL / 6 male mice were purchased from Shanghai Slack Experimental Animal Co., Ltd. and raised in SPF environment. Standard diet AIN-76A (iron content 50 mg / Kg, Research Diets, Inc) was adapted to feeding for 2 weeks, and randomly divided into groups according to body weight, with 6-8 animals in each group.

[0019] 1.2 Drugs and treatment

[0020] Compounds zinc protoporphyrin (ZnPP) and doxorubicin (DOX) were purchased from Sigma-Aldrich Company. Doxorubicin was dissolved in saline, and zinc protoporphyrin was dissolved in dimethyl sulfoxide (DMSO). Doxorubicin was injected intraperitoneally once at 10 mg / kg body weight; zinc protoporphyrin was injected intraperitoneally one day before doxorubicin injec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an HO (Heme Oxygenase)-1 inhibitor in preparing medicine for treating cardiotoxicity induced by anti-cancer medicine-doxorubicin. The HO-1 inhibitor is zinc protoporphyrin. According to the application disclosed by the invention, basis is provided for new drug research and development and innovative therapy.

Description

technical field [0001] The invention relates to heme oxygenase-1 inhibitor zinc protoporphyrin (Zinc protoporphyrin, ZnPP), which can significantly reduce cardiotoxicity caused by doxorubicin when used in combination with antitumor drug doxorubicin. Background technique [0002] Doxorubicin (DOX) belongs to anthracycline antitumor antibiotics. It has the characteristics of broad antitumor spectrum, strong antitumor effect and definite curative effect. It is widely used in the treatment of hematological malignancies and solid tumors, such as acute leukemia, lymph cancer, breast cancer, gastric cancer, soft tissue sarcoma and ovarian cancer. Similar to other antineoplastic drugs, doxorubicin has a strong damaging effect on cancerous cells on the one hand, and is also toxic to normal cells and tissues on the other hand, which can cause toxic side effects such as hair loss, bone marrow suppression, and cardiotoxicity. Among them, the biggest side effect of doxorubicin is irreve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/555A61P9/00
CPCA61K31/555
Inventor 王福俤方学贤韩丹王浩闵军霞
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com